Longer-term open-label study of adjunctive riluzole in treatment-resistant depression.
Longer-term open-label study of adjunctive riluzole in treatment-resistant depression.
复制标题
辅助利鲁唑治疗难治性抑郁症的长期开放标签研究。
DOI：
10.1016/j.jad.2019.06.065
复制
发表时间：
2019
影响因子：
6.6
通讯作者：
Cusin,Cristina
中科院分区：
文献类型：
--
作者：
Sakurai,Hitoshi;Dording,Christina;Yeung,Albert;Foster,Simmie;Jain,Felipe;Chang,Trina;Trinh,Nhi-Ha;Bernard,Richard;Boyden,Sean;Iqbal,SyedZ;Wilkinson,SamuelT;Mathew,SanjayJ;Mischoulon,David;Fava,Maurizio;Cusin,Cristina
虽然利鲁唑已被研究用于治疗抑郁症，但其在难治性抑郁症（TRD）中的长期疗效和最佳治疗持续时间却知之甚少。本研究的目的是描述连续利鲁唑治疗TRD的长期结果在一个开放标签的扩展8周的急性治疗trial.MethodsThe数据从66例TRD谁收到连续利鲁唑在12周的开放标签扩展阶段进行了分析。应答率（Mongomery-Asberg抑郁评定量表[MADRS]评分降低≥ 50%），复发率（MADRS评分为10.22，在先前已达到反应的患者中），并在急性期结束时达到反应的患者和未达到反应的患者中检查不良事件。维持有效率66.7%（8/12），复发率8.3%（1/12）。在急性期无应答者中，应答率为24.1%（13/54）。最常见的不良事件是疲劳（9.1%）。三例病例被认为是严重不良事件;呕吐（n= 1）、呼吸急促（n= 1）和自杀未遂（n= 1）。局限性这项长期研究是开放标签且不受控制的。样本量相对较小。ConclusionsLonger-term连续利鲁唑出现相对较好的耐受性和有利于维持以前的反应。此外，大约四分之一的患者对8周抗抑郁药治疗无反应，如果用利鲁唑治疗12周，可能会有反应。这些发现值得进一步研究，因为当标准抗抑郁药失败时，服用利鲁唑可能是治疗抑郁症的一种选择。
BackgroundWhile riluzole has been investigated for the treatment of depression, little is known about its longer-term efficacy and optimal treatment duration in treatment-resistant depression (TRD). The objective of this study is to characterize the longer-term outcome of adjunctive riluzole therapy for TRD in an open-label extension of an 8-week acute treatment trial.MethodsThe data from 66 patients with TRD who received adjunctive riluzole in a 12-week open-label extension phase were analyzed. Response rates (⩾50% reduction in the Mongomery-Asberg Depression Rating Scale [MADRS] score), relapse rates (a MADRS score of ⩾22 in patients who had previously achieved response), and adverse events were examined in patients who had achieved response at the end of the acute phase and those who had not.ResultsAmong acute phase responders, the maintained response rate was 66.7% (8/12) and the relapse rate was 8.3% (1/12). In acute phase non-responders, the response rate was 24.1% (13/54). The most commonly reported adverse event was fatigue (9.1%). Three cases were considered serious adverse events; vomiting (n= 1), shortness of breath (n= 1), and aborted suicide attempt (n= 1).LimitationsThis longer-term study was open-label and uncontrolled. The sample size was relatively small.ConclusionsLonger-term adjunctive riluzole appears relatively well tolerated and beneficial for maintaining previous response. Additionally, approximately one fourth of patients who did not respond to 8-week antidepressant treatment might respond if treated with riluzole for 12 weeks. Those findings warrant further investigation because adjunctive riluzole could represent an option for treatment of depression when standard antidepressants have failed.